Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulations

Yan Li¹, Duxin Sun², Maria Palmisano¹ & Simon Zhou¹

¹Translational Development and Clinical Pharmacology, Celgene Corporation, 86 Morris Avenue, Summit, 07920 New Jersey
²College of Pharmacy, the University of Michigan, Ann Arbor, 48109 Michigan

Abstract

Oxycodone is a commonly used analgesic with a large body of pharmacokinetic data from various immediate-release or controlled-release formulations, under different administration routes, and in diverse populations. Longer terminal half-lives from extravascular administration as compared to IV administration have been attributed to flip-flop pharmacokinetics with the rate constant of absorption slower than elimination. However, PK parameters from the extravascular studies showed faster absorption than elimination. Sustained release formulations guided by the flip-flop concept produced mixed outcomes in formulation development and clinical studies. This research aims to develop a mechanistic knowledge of oxycodone ADME, and provide a consistent interpretation of diverging results and insight to guide further extended release development and optimize the clinical use of oxycodone. PK data of oxycodone in human studies were collected from literature and digitized. The PK data were analyzed using a new PK model with Weibull function to describe time-varying drug releases/ oral absorption, and elimination dependent upon drug input to the portal vein. The new and traditional PK models were coded in NONMEM. Sensitivity analyses were conducted to address the relationship between rates of drug release/absorption and PK profiles plus terminal half-lives. Traditional PK model could not be applied consistently to describe drug absorption and elimination of oxycodone. Errors were forced on absorption, elimination, or both parameters when IV and PO profiles were fitted separately. The new mechanistic PK model with Weibull function on absorption and slower total body clearance caused by slower absorption adequately describes the complex interplay between oxycodone absorption and elimination in vivo. Terminal phase of oxycodone PK profile was shown to reflect slower total body drug clearance due to slower drug release/absorption from oral formulations. Mechanistic PK models with Weibull absorption functions, and release rate-dependent saturable total body clearance well described the diverging oxycodone absorption and elimination kinetics in the literature. It showed no actual drug absorption during the terminal phase, but slower drug clearance caused by slower release/absorption producing the appearance of flip-flop and offered new insight for the development of modified release formulations and clinical use of oxycodone.

Abbreviations

ADME, absorption, distribution, metabolism and excretion; AUC, area under the curve; BID, twice (two times) a day; CL→intrinsic, in vivo intrinsic clearance; CL, total body clearance; C→max, the maximum plasma concentration; CR, controlled-release;
Introduction

Oxycodone (14-hydroxy-7,8-dihydrocodeinone) is one of the most studied and widely used analgesics (Ross and Smith 1997; Smith 2008). It has been administered intravenously (i.v.) (Takala et al. 1997; Kokki et al. 2004; Hao et al. 2014; Kokubun et al. 2014), intramuscularly (i.m.) (Kokki et al. 2004), intranasally (i.n.) (Takala et al. 1997; Dale et al. 2002), subcutaneously (s.c.) (Kokubun et al. 2014), buccally (Kokki et al. 2004), rectally (Tegon et al. 2009; Li et al. 2011), epidurally (Kokki et al. 2014), and orally (Mandema et al. 1996; Bass et al. 2012; Mundin et al. 2012; Kim et al. 2015) using immediate release (IR) solutions and immediate- and controlled-release tablets to diverse disease populations for the treatment of acute, and chronic nonmalignant pain and cancer pain (Hanks et al. 2001; Radbruch and Nauck 2002; Lux et al. 2014; Mehta et al. 2014; Stessel et al. 2014; Poelaert et al. 2015).

Oxycodone has been shown to have consistent pharmacokinetic properties and pharmacologic activities in diverse ethnic populations of Caucasians, Japanese, and Chinese (Hao et al. 2014; Kokubun et al. 2014). Oxycodone is relatively well absorbed after oral administration, and commercially available IR and ER formulations have a bioavailability of 40–80% (Mandema et al. 1996; Bass et al. 2012; Mundin et al. 2012; Kim et al. 2015). The sublingual bioavailability of oxycodone is less than 20% at normal pH (Al-Ghananeem et al. 2006). The mean bioavailability of intranasal oxycodone is 46%, but there is wide interindividual variability from 16% to 100% (Lofwall et al. 2012). Approximately, 40% of oxycodone is bound to plasma proteins in vitro (Vallejo et al. 2011). Approximately, 99% of oxycodone is distributed outside the plasma compartment, as reflected by the large volume of distribution of oxycodone (2–3 L/kg). The main known metabolic pathways of oxycodone are through O-demethylation to oxymorphone via CYP2D6 and through N-demethylation to noroxycodone via CYP 3A4 (Lalovic et al. 2006; Gronlund et al. 2011; Naito et al. 2013; Soderberg Lofdal et al. 2013). Oxycodone itself is the major contributor to the analgesic effect following oxycodone administration. Although two of the metabolites, in particular oxymorphone, have higher affinities for the μ-receptors, their contribution to the overall analgesic effect is insignificant (Trescot et al. 2008). Total plasma clearance of oxycodone in adults is 0.7–1 L/min, which is consistent with intermediate hepatic extraction and a moderate first-pass effect. The T1/2 is about 2–3 h after i.v. administration, about 3 h after IR solution and about 8 h after controlled-release (CR) oxycodone (Mandema et al. 1996; Kokki et al. 2004; Bass et al. 2012).

Though a large body of pharmacokinetics data have been accumulated and effectively advanced the knowledge of pharmacokinetic disposition of oxycodone, gaps remain in the explanation of the diverging pharmacokinetic parameter values derived from IV and PO administration of oxycodone solutions, and between distinct PK parameters derived from oral administration of IR and ER formulations. Among these, one particular problem stands out on how to correctly disentangle oxycodone oral absorption from its elimination. Compared to IV administration, longer half-lives of oxycodone following PO administration has been attributed to flip-flop kinetics in which the rate of oxycodone oral absorption is slower than that of elimination, however, PK parameters derived from oral administration of IR and ER formulations showed the absorption rate constant is much faster than the elimination rate constant contradicting the traditional concept of flip-flop kinetics. In addition, the pharmacokinetic parameters by traditional noncompartment and compartment modeling from IV and various PO administrations varied significantly and sometimes were against common pharmacological understanding (especially discordant apparent volume of distribution and apparent total body clearance). Furthermore, guided by the flip-flop concept, efforts to slow oxycodone release, which have been the mainstay for BID and QD sustained release formulations, produced somewhat mixed outcomes in formulations development and clinical studies (Mandema et al. 1996; Bass et al. 2012; Mundin et al. 2012; Kim et al. 2015).

The purpose of this investigation is to survey the existing literature and develop a consistent mechanistic model for
the divergent pharmacokinetics of oxycodone after IV and PO administration of IR and ER formulations; and provides new insight into oxycodone disposition and a consistent framework of oxycodone ADME to guide further extended release development and optimize the clinical use of oxycodone.

**Materials and Methods**

**Oxycodone plasma concentration–time data**

Plasma oxycodone concentration–time data were obtained from eight manuscripts (Mandema et al. 1996; Takala et al. 1997; Kokki et al. 2004; Bass et al. 2012; Mundin et al. 2012; Hao et al. 2014; Kokubun et al. 2014; Kim et al. 2015). The data covered a wide dose range from 5 to 20 mg following IV and extravascular administration using immediate and modified release formulations under fasted and fed conditions. Table 1 summarizes the doses, types of formulations and routes of administration for each study.

All the manuscripts were either obtained in digital pdf format or scanned from paper copies into pdf formatted files. The electronic plasma concentration–time profile were then digitized using UN-SCAN-IT Graph Digitizing Software version 6.0 (Silk Scientific Inc., Orem, UT) software to obtain the plasma concentration and time data.

**Noncompartmental PK analyses**

Plasma concentration–time data of oxycodone were analyzed using noncompartmental PK methodology with Phoenix WinNonlin (CERTARA, Princeton, NJ). The Cmax was the highest concentrations based on the plasma concentration–time data, while the AUC were calculated using trapezoidal rules. PK parameters of V/F, CL/F, T1/2, and etc. were estimated based on the standard non-parametric methodology in WinNonlin.

**Compartmental PK analyses**

Compartmental model PK analyses were performed in nonlinear mixed-effect model (NONMEM), version 7.2 (ICON Development Solutions, Hanover, MD). One-compartment model was parameterized in Ka, CL, and V using ADVAN2, TRANS2 routine, while two-compartment model was parameterized in K, CL, Q, V2, and V3 using ADVAN4 and TRANS4 routine in NONMEM.

Weibull function is frequently applied to the analysis of dissolution and release studies of drug formulations (Gomez-Mantilla et al. 2013, 2014; Tan et al. 2013). The success of Weibull functions in describing drug release from oral formulations have been shown to capture concentration gradients near the releasing boundaries of the Euclidian matrix (Kosmidis and Argyrakis 2003), as well as adequately describe the fractal kinetics behavior associated with the fractal geometry of the dissolution environment. In addition, due to its versatile and flexible forms, Weibull function has been used numerically to describe complex plasma concentration–time profiles of oral absorption of drugs (Vkt 1987; Zhou 2003). To describe the convex ascending oxycodone plasma concentration–time profile prior to Cmax, a time-varying Weibull function was introduced to describe time-varying absorption rate constant as follows:

\[
f(x; \lambda, k) = \begin{cases} \frac{k}{\lambda} (\frac{x}{\lambda})^{k-1} & x \geq 0, \\ 0 & x < 0, \end{cases}
\]

The absorption rate defined by Weibull absorption was coded in NONMEM as follows:

| Study number | Dose | Type of formulation | Route of administration |
|--------------|------|---------------------|-------------------------|
| 1. Hao et al. (2014) | 2.5, 5 and 10 mg | Oxycodone hydrochloride solution | IV |
| 2. Mandema et al. (1996) | 20 mg | IR solution and CR tablet | PO |
| 3. Kokki et al. (2004) | 0.1 mg/kg | Oxycodone hydrochloride solution | IV, intramuscularly, and buccally |
| 4. Bass et al. (2012) | 5, 10, and 15 mg | An immediate-release oxycodone hydrochloride formulation (IRO-A) and marketed oxycodone hydrochloride (IRO) tablets | PO |
| 5. Takala et al. (1997) | 0.05 mg/kg | Oxycodone hydrochloride solution | IV and intranasal |
| 6. Kokubun et al. (2014) | 5 mg | Oxycodone hydrochloride solution | IV |
| 7. Mundin et al. (2012) | 20 mg | Slow, median, and fast dissolution formulations of tablets | PO |
| 8. Kim et al. (2015) | 10 and 20 mg | IR and CR | PO |

IV, intravenously; PO, orally; IR, immediate-release; CR, controlled-release; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation.
ALPHA = THETA(1) × EXP(ETA(1)); where θ1 is the rate constants (λ) of Weibull distribution
BETA = THETA(2) × EXP(ETA(2)); where θ2 is the Weibull shape (κ) of Weibull distribution
KA = BETA/ALPHA × (TIME/ALPHA) × (BETA-1) × EXP(-1 × (TIME/ALPHA) × BETA)

Though it not easy to ascribe the physical interpretation of the Weibull shape (κ) and rate constants (λ/da), one can draw analogy of drug release as a function changing with time (such as release rate increases, decreases, or not change with time) and also associated with a shape distribution.

The concept that the total body drug clearance is function of its intrinsic clearance rate and blood flow delivering drug to the clearance organ was first introduced by Pang and Rowland (1977) using the well-stirred tank model as:

\[ CL = \frac{CL_{\text{intrinsic}}Q_h}{CL_{\text{intrinsic}} + Q_h} \]  

(2)

where CL is the observed total body clearance, CLintrinsic is the intrinsic clearance defined as \( \frac{V_m}{K_m} \) of metabolic rate of Michaelis–Menten kinetics, Qh is the drug input rate into the blood flow feeding into clearance organ (portal liver blood flow for IV administration for metabolism). Total body clearance as defined by Equation (2) has been successfully applied to classify drugs into two categories of high and low extraction ratios. And it has been shown in theory and practice that total body clearance of drugs with high extraction ratio is limited by the rate of blood flow feeding into the clearance organ of liver or kidney, while the total body clearance of drugs with low extraction ratio is determined by its intrinsic clearance. As for drugs with mild to moderate intrinsic clearance, its total body clearance is defined by equation (2). For intravenously administered oxycodone, CLintrinsic of oxycodone can be estimated based on observed total body clearance (CLtotal) and liver blood flow Qh of 84 L/h. When oxycodone was administered orally in IR or ER formulations, the drug release rates from the formulations may be slower than rate of portal liver blood flow and thus reduce the drug input rate to liver. Therefore, the total body clearance for orally administered oxycodone would be determined by the drug release rate from the IR or ER formulations and the intrinsic oxycodone clearance defined by equation (2).

Since there is no reason to suppose route of oxycodone administration would change it intrinsic distribution and clearance properties. A single set of PK parameters of intrinsic oxycodone clearance, oxycodone volume of distribution and rate of distribution were employed to simultaneously fitting of oxycodone plasma concentra-

**Results**

**Noncompartmental and traditional one compartmental analysis**

Mean plasma concentration–time data of oxycodone following oral administration of immediate and sustained release formulations at 5–20 mg and intranasal administration at 6.7 mg were shown in Figure 1. After reaching the peak concentration of Cmax, the oxycodone plasma concentrations followed a monoexponential decline. The terminal phases of the plasma concentration–time profiles had distinct half-lives with PO administration of immediate-release (IR) and controlled-release (CR) or with intranasal administration. These data were analyzed using noncompartmental and traditional compartmental analyses by way of one-compartment model with first-order rate constants. The results from noncompartmental and traditional compartmental analyses were tabulated in Tables 2, 3, together with the PK parameter values reported from the original manuscripts.

Consistent with original literature, both noncompartmental and compartmental analyses for different doses and formulations resulted in significantly distinct sets of PK parameters. Though PK profiles were adequately described by different set of PK parameters, it is difficult to relate the PK parameters to the underlying ADME processes. The wide range of apparent volume distribu-
tion from 397.43 to 1415.98 L based on noncompartmen-
tal analysis or from 28.1 to 1521 L based on one-com-
partment analysis, and relatively narrow range of
apparent total body clearance from 74 to 120 L/h sug-
gested disproportional effect on oxycodone intrinsic dis-
tribution and intrinsic elimination parameters (ratio of
apparent volume of distribution and apparent clearance
\(\frac{CL}{V}\)). It is particularly perplexing that different route of
drug delivery and different rate of oral delivery from IR
to ER would change the intrinsic distribution and elimi-
nation of oxycodone, against the common pharmacology
understanding that drug distribution and elimination are
intrinsic to the molecule and agnostic to the path on
which it arrives into the blood circulation.

### Two-compartment analyses of the IV data to
assess the intrinsic oxycodone distribution and total body clearance

Plasma concentration–time data following intravenous
administration of oxycodone at 2.5, 5, and 10 mg in
Chinese; at 5 mg in Japanese; at 0.05 mg/kg in adult
Caucasians; and at 0.1 mg/kg in Caucasian Children from

---

![Figure 1. Mean plasma concentration–time profile of oxycodone from different doses, different types of formulations, and different routes of extravascular administration.](image)

**Table 2.** PK parameter estimates from noncompartmental analyses.

| Study | Dose (mg) | Formulation/route | \(t_{1/2}\) (h) | \(V_z/F\) (L) | CL/F (L/h) |
|-------|-----------|-------------------|--------------|-------------|-----------|
|       |           |                   | Estimated    | Reported    | Estimated | Reported |
| 2     | 20        | CR                | 8.42         | 7.99 ± 2.96 | 1097.62   | 90.37     |
| 2     | 20        | IR                | 3.70         | 3.21 ± 0.87 | 539.86    | 101.16    |
| 4     | 5         | IRO-A 5 mg fasted | 3.24         | 3.24        | 479.12    | 102.40    |
| 4     | 10        | IRO-A 10 mg fasted| 3.72         | 3.38        | 544.84    | 101.41    |
| 4     | 15        | IRO 15 mg fed     | 3.47         | 3.57        | 397.43    | 79.45     |
| 4     | 15        | IRO-A 15 mg fasted| 3.25         | 3.71        | 459.23    | 97.80     |
| 5     | 6.7       | Intranasal        | 5.58         | 5.58        | 794.83    | 98.72     |
| 8     | 10        | IR-bid            | 8.81         | 8.81        | 676.62    | 106.48    |
| 8     | 20        | CR-qd             | 12.82        | 12.82       | 1415.98   | 76.59     |

\(t_{1/2}\), terminal half-life; \(V_z/F\), terminal volume of distribution; CL/F, apparent total body clearance; CR, controlled-release; IR, immediate-release; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation; bid, twice daily; qd, once daily.
studies 1, 3, 5, and 6 (Takala et al. 1997; Kokki et al. 2004; Hao et al. 2014; Kokubun et al. 2014) and goodness of fit of the two-compartment analyses of the IV data to assess the intrinsic oxycodone distribution and clearance. Solid lines: observed data; dotted lines: model predicted data were shown in Figure 2. The IV oxycodone PK profiles followed a biphasic decline and were adequately described by a two-compartment structure model, and a single set of intrinsic PK parameters across a wide dose range in diverse populations (Table 4). Consistent with known oxycodone ADME characteristics, larger volume of distribution from peripheral compartment as compared to volume of distribution from central compartment (105 vs. 39.2 L) and larger intercompartment clearance as compared to total body clearance (199 vs. 39.8 L/h) suggest that oxycodone is rapidly and extensively distributed into tissue following intravenous administration. In addition, high in vivo intrinsic clearance (CL\textsubscript{intrinsic}) of 75.8 L/h estimated from the modeling is consistent with its moderate hepatic extraction and first-pass effect.

### Two-compartment analyses with first-order absorption rate constant and saturable elimination affected by slower drug input to portal vein

The plasma concentration–time data following both IV and PO administration of oxycodone IR and CR formulations from studies 2 and 8 (Mandema et al. 1996; Kim et al. 2015) were analyzed simultaneously using a two-compartment model with first-order absorption rate constant and saturable elimination affected by slower drug input to portal vein defined by Equation 2 and common set of PK parameters on oxycodone distribution. The results from the analyses were shown in Table 5, and the goodness of fit of the model was shown in Figure 3.

As shown in Figure 3, the model with input rate-dependent clearance provided good fit of both the absorption and the terminal phases of IV and PO profiles of IR and CR formulations with distinct half-lives.

| Study | Dose (mg) | Formulation/route | $K_a$ (1/h) | $V/F$ (L) | CL/F (L) |
|-------|-----------|-------------------|-------------|----------|----------|
| 2     | 20        | CR                | 0.70        | 1120.3   | 88.8     |
| 2     | 20        | IR                | 2.99        | 540.6    | 102.6    |
| 4     | 5         | IRO-A 5 mg fasted | 0.24        | 114.7    | 102.7    |
| 4     | 10        | IRO-A 10 mg fasted| 0.22        | 97.2     | 101.4    |
| 4     | 15        | IRO-A 15 mg fasted| 0.23        | 102.0    | 98.5     |
| 4     | 15        | IRO-A 15 mg fed   | 0.19        | 203.6    | 82.1     |
| 4     | 15        | IRO 15 mg fed     | 0.22        | 76.1     | 79.2     |
| 5     | 6.7       | Intranasal        | 0.15        | 28.1     | 105.4    |
| 8     | 10        | IR-bid            | 0.08        | 73.3     | 77.4     |
| 8     | 20        | CR-qd             | 0.61        | 1521.9   | 73.5     |

$K_a$, absorption rate constant; V/F, apparent volume of distribution; CL/F, apparent total body clearance; CR, controlled-release; IR, immediate-release; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation; bid, twice daily; qd, once daily.

**Table 3. PK parameter estimates from one-compartment analyses.**

Figure 2. Mean plasma concentration–time profile of oxycodone from different doses under IV administration and goodness of fit of the two-compartment analyses of the IV data to assess the intrinsic oxycodone distribution and clearance. Solid lines, observed data; dotted lines, model predicted data.

© 2016 Celgene Inc. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Table 4. Intrinsic oxycodone PK parameter estimates from IV administration.

| PK parameter | Mean   | 90% CI | 1Nonparametric 90% CI (5–95 percentiles) from the 100 bootstrap. |
|--------------|--------|--------|-----------------------------------------------------------------|
| V2 (L)       | 39.2   | (22.3, 64.6) |
| V3 (L)       | 105    | (73.4, 143.9) |
| Q (L/h)      | 199    | (89.3, 356.2) |
| Cl_{intrinsic} (L/h) | 75.8   | (49.4, 108.3) |
| Q_i (L/h)    | 84     | FIXED  |
| Cl (L/h)     | 39.8   |        |

Cl, confident interval; V2, volume of distribution of central compartment; V3, volume of distribution of peripheral compartment; Q, intercompartment clearance; Cl_{intrinsic}, in vivo intrinsic clearance; Q_i, the drug input rate into the blood flow feeding into clearance organ (portal liver blood flow for IV administration); Cl, clearance defined by Equation 2.

Two-compartment analyses with Weibull absorption and saturable total body elimination affected by slower drug input to portal vein

The plasma concentration–time data following both IV and PO administration of oxycodone IR formulations from study 4 (Bass et al. 2012) were initially analyzed simultaneously using a two-compartment model with first-order absorption rate constant and saturable elimination affected by slower drug input to portal vein (Fig. 4). The model provided good fit of the terminal phases of IV and PO profiles. However, this model did not well characterize the absorption phases of different formulations. A time-varying Weibull function was introduced to describe time-varying profiles. The results from the analyses were shown in Table 6, and the goodness of fit of the model was shown in Figure 4.

As shown in Figure 4, the model with Weibull distribution improved the model fit during the absorption phase of oxycodone PK profile over the constant rate of absorption, while input rate-dependent total body clearance provided good fit of the terminal phase of IV and PO profiles of IR and CR formulation with distinct half-lives.

Two-compartment analyses with Weibull absorption and saturable elimination affected by slower drug input to portal vein under intranasal administration

The oxycodone plasma concentration following intranasal administration from study 5 (Takala et al. 1997) (shown in Fig. 1) were analyzed using a two-compartment model with Weibull absorption and saturable elimination affected by slower drug input to portal vein and common set of PK parameters on oxycodone distribution based on IV data. The results from the analyses were shown in Table 6, and the goodness of fit of the model was shown in Figure 5. Again, the model provided good fit of both the intranasal absorption and the terminal phase of intranasal PK profile.

Table 5. PK parameter estimates from two-compartment analyses with first-order absorption rate constant and saturable elimination affected by slower drug inputs to portal vein.

| Study | Formulation/route | V2 (L) | V3 (L) | Q (L/h) | Cl_{intrinsic} (L/h) | KA (1/h) | Q_i (L/h) | F1 | CL (L/h) |
|-------|-------------------|--------|--------|---------|----------------------|----------|----------|----|----------|
| 2     | CR/PO             | 39     | 105    | 199     | 75.8                 | 84       | 20.4     | 17.5|          |
| 2     | IR/PO             | 1.34   | 54.7   | 33.6    | 9.0                  | 6.7      | 10.6     |    |          |
| 8     | CR (qd)/PO        | 0.477  | 7.4    | 9.0     | 6.7                  | 10.6     |          |    |          |
| 8     | Commercial IR (bid)/PO | 0.886 | 12.3   | 13.9    | 10.6                |          |          |    |          |

V2, volume of distribution of central compartment; V3, volume of distribution of peripheral compartment; Q, intercompartment clearance; Cl_{intrinsic}, in vivo intrinsic clearance; Q_i, the drug input rate into the blood flow feeding into clearance organ (portal liver blood flow for IV administration); F1, bioavailability; CL, clearance defined by Equation 2; IV, intravenous; CR, controlled-release; PO, orally; IR, immediate-release; qd, once daily; bid, twice daily.
As shown in Figure 6, the model with input rate-dependent total body clearance provided good model fit of orally administered oxycodone PK profile. The results derived from the oral data without IV data were similar to those derived with both IV and oral data. Further, though the apparent volume of distribution following IR administration has increased due to confounding F, the magnitude of change in V/F and apparent total body clearance CL/F following ER administration was 40% and 18%, respectively, tracking the 38% and 14% change estimated from with the IV data. In addition, the model developed based on oxycodone IV and PO administration of IR and ER formulations provided adequate fit of oxycodone PK profiles from separate sources of modified release efforts.

**Discussion**

Oxycodone is a drug with moderately high total body clearance of ~34–47 L/h (in comparison of 86 L/h liver blood flow) following a bolus IV dose (Kalso 2005). Interestingly, when oxycodone was administered in a slow intravenous infusion of ~1 mg/h to Japanese patients, its total body clearance decreased from ~34 L/h following a bolus intravenous injection to 24.3 L/h indicating that oxycodone total body clearance following intravenous administration is sensitive to its input rate to blood (Kokubun et al. 2014). Assuming a typical liver blood flow of 86 L/h, the intrinsic hepatic clearance of oxycodone is estimated to be 76 L/h using equation 2. With these typical values, slower intravenous infusion regimen may be designed to exploit the decreased oxycodone total body clearance with slow infusion rate to maximize the oxycodone plasma exposure and associated benefit and outcome for patients under intensive care in clinics.

Though intravenously administered bolus oxycodone behaved consistently across wide dose ranges and in diverse populations with dose proportional exposure and consistent distribution and elimination characteristics (Table 2 in results), there is considerable variability in oral oxycodone bioavailability reported in the literature, depending on the formulations tested. The findings of this research offer a new mechanistic explanation of the large variability in oxycodone oral bioavailability. For
drug like oxycodone with high intrinsic clearance and high liver extraction ratio, its total body clearance is largely determined by the blood flow feeding into the metabolic enzymes. When the rate of drug release from oral formulations is much slower than the intrinsic oxycodone clearance rate, the total body clearance of oxycodone is largely determined by the slow drug release rate from the formulations. Therefore, different IR and ER formulations with distinct oxycodone release rates will cause different oxycodone total body clearance and significantly affect

**Figure 4.** Goodness of fit of the two-compartment analyses with first-order absorption rate constant or Weibull absorption and saturable elimination affected by slower drug input to portal vein for (A) IRO-A 5 mg fasted data, (B) IRO-A 10 mg fasted data, (C) IRO-A 15 mg fasted data, (D) IRO-A 15 mg fed data, (E) IRO 15 mg fed data. Observed, observed concentrations; IPRE ($k_a$ constant), model predicted concentrations with first-order absorption rate constant; IPRE (Weibull), model predicted concentrations with Weibull absorption.

**Table 6.** PK parameter estimates from two-compartment analyses with Weibull absorption and saturable elimination affected by slower drug inputs to portal vein.

| Study | Formulation/route | V2 (L) | V3 (L) | Q (L/h) | $\text{CL}_{\text{intrinsic}}$ (L/h) | $\lambda$ | $\kappa$ | $Q_h$ (L/h) | F1 (%) | CL (L/h) |
|-------|------------------|--------|--------|---------|----------------|--------|---------|----------|--------|---------|
| IV    | Intransal        | 39     | 105    | 199     | 75.8           | 84     |         | 39.8     |
| 5     | IRO-A 5 mg fasted| 0.465  | 1.92   | 21.4    | 29.9           | 16.7   |
| 4     | IRO-A 10 mg fasted| 0.878  | 3.64   | 31.0    | 34.9           | 22.0   |
| 4     | IRO-A 15 mg fasted| 0.958  | 3.2    | 32.7    | 37.0           | 22.8   |
| 4     | IRO-A 15 mg fed  | 0.806  | 3.86   | 29.5    | 35.1           | 21.2   |
| 4     | IRO 15 mg fed    | 2.21   | 2.68   | 26.6    | 40.1           | 19.7   |
| 4     | IRO 15 mg fed    | 0.833  | 4.03   | 26.6    | 39.7           | 19.7   |

V2, volume of distribution of central compartment; V3, volume of distribution of peripheral compartment; Q, intercompartment clearance; $\text{CL}_{\text{intrinsic}}$, in vivo intrinsic clearance; $\lambda$, $k$ factor of Weibull distribution; $\kappa$, $\kappa$ factor of Weibull distribution; $Q_h$, the drug input rate into the blood flow feeding into clearance organ (portal liver blood flow for IV administration); F1, bioavailability; CL, clearance defined by Equation 2; IV, intravenous; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation.
the first-pass extraction and bioavailability of oxycodone (Table 5, 6, and 7 in the results).

There was also considerable variation in the apparent volume of distribution and apparent total body clearance reported in the literature (Table 1). The lack of concordance between the changes in apparent volume of distribution and apparent total body clearance were most puzzling and contradicted the traditional pharmacokinetic concept that route of drug administration should only affect a drug’s systemic bioavailability, but not affect its intrinsic distribution and dispositional characteristics. The findings of this research offer new insight into this incongruence and provide a new and consistent mechanistic explanation on the discordant effect of different routes of oxycodone delivery on its apparent volume of distribution and apparent total body clearance. The slower drug release rates from different IR and ER oral formulations and intranasal administrations causes slower effective oxycodone blood input rate and results in slower oxycodone total body clearance. In addition to the different extent of first-pass effect caused by slower oxycodone release from IR or ER oral formulations and intranasal administration, the slower oxycodone release also affected the fraction of dose absorbed and complicated the eventual systemic bioavailability of oxycodone. While the route and rates of oxycodone delivery does not affect its distribution characteristics, the route and rate do affect the denominator, but NOT the nominator on the estimation of apparent volume distribution in V/F. However, route and rate of oxycodone delivery directly changes oxycodone total body clearance rate and indirectly affect the fraction of oxycodone absorbed (Table 2), as such the total effect would be on both the nominator and denominator in estimation of apparent total body clearance in CL/F; consequently, apparent volume of distribution would become disparate from the apparent total body clearance estimation by traditional noncompartmental analyses and one-compartment analyses (Table 1).

Furthermore, different terminal half-lives from different oral formulations had been traditionally attributed to flip-flop kinetics, that is, slower oral absorption reflected the terminal half-lives rather than the different oxycodone total body clearance as a result of slower absorption. However, upon closer examination, the rate of oxycodone oral absorption based on noncompartmental or one-compartment analysis have invariably yielded a more rapid absorption rate constant than the elimination rate constant (Table 1). Based on the findings of this research, the slower oxycodone input to liver portal vein affected slower oxycodone total body clearance, but did not affect oxycodone distribution causing a shallower slope of

Table 7. PK parameter estimates from sensitivity analysis.

|          | IR        | CR        |
|----------|-----------|-----------|
| KA (1/h) | 2.99      | 0.698     |
| V (L)    | 541       | 541       |
| CL (L/h) | 103       | 42.8      |
| F1 (CR/IR)| 1        | 48.3%     |

Ka, absorption rate constant; V, volume of distribution; CL, clearance; F1, relative bioavailability to IR formulation; IR, immediate-release; CR, controlled-release.
terminal elimination phase (kel) by way of CL/V. Thus, the terminal phase of oxycodone PK profile is a direct result of slower oxycodone total body clearance which is caused by slower oxycodone release. Though the rate of oral oxycodone absorption in modified release formulations and extravascular delivery is still much faster than the rate of oxycodone total body clearance and would be not reflected in its terminal phase of oxycodone PK profile, the longer terminal elimination phase would actually reflect its slower total body clearance as a result of the slower oxycodone absorption.

Oral absorption of oxycodone is rapid, as reflected by large rate constant from the one- and two-compartment model analyses. The first-order release and oral absorption is a reasonable approximation with a rapid ascending oxycodone plasma concentration–time profile for IR and certain ER formulations (Table 2 and Fig. 2) when oxycodone release is fast. However, when the rate of oxycodone release is modified and oxycodone is taken with food, the resulting convex and/or sigmoid plasma concentration–time during the absorption phase was better described with a time-varying Weibull absorption rate function (Fig. 3). The Weibull function appeared to capture the dynamic time-varying nature of oxycodone better than the first-order release with a constant rate, and more likely reflected the physical dissolution and physiological conditions of GI track.

The insights from this research shed new light on the strategy of modified release oxycodone development. In the past, efforts have been directed to delay and slow oxycodone release in proximal intestine and increase distal intestinal absorption of oxycodone. However, findings from this research indicate that distal intestinal absorption of oxycodone is poor and slow. Compared to IR oxycodone, the elevation in plasma concentration of oxycodone following Cmax by modified release formulations is a product of slower oxycodone total body clearance and decreasing oxycodone absorption. Rather than delaying release of oxycodone, optimization may be achieved by modifying the rate of oxycodone release in proximal intestine to maximize the fraction of oxycodone absorbed while slowing oxycodone total body clearance.

**Acknowledgements**

The authors are fully responsible for the content and editorial decisions for this manuscript. The authors acknowledge the financial support for this study from Celgene Corporation.

**Author Contributions**

Participated in research design: Li, Sun, Palmisano, Zhou.

Contributed new reagents or analytic tools: N/A.

Performed data analysis: Li, Zhou.

Wrote or contributed to the writing of the manuscript: Li, Sun, Palmisano, Zhou.

**Disclosures**

None declared.
**References**

Al-Ghananeem AM, Malkawi AH, Crooks PA (2006). Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS Pharm Sci Tech 7: E23.

Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, et al. (2012). Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Clin Ther 34: 1601–1612.

Dale O, Hjortkjaer R, Kharasch ED (2002). Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46: 759–770.

Gomez-Mantilla JD, Casabo VG, Schaefer UF, Permutation Lehr CM (2013). Permutation test (PT) and tolerated difference test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. Int J Pharm 441: 458–467.

Gomez-Mantilla JD, Schaefer UF, Casabo VG, Lehr T, Lehr CM (2014). Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. Aaps J 16: 791–801.

Gronlund J, Saari TI, Hagelberg N, Neuvonen PJ, Olkkola KT, Miconazole Laine K (2011). Oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrob Agents Chemother 55: 1063–1067.

Hanks GW, Conno F, Cherry N, Hanna M, Kalso E, McQuay HJ, et al. (2001). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593.

Hao GT, Zhou HY, Gao HZ, Qu HY, Liang YG, Li YY, et al. (2014). Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Pharmocol Rep 66: 153–158.

Kalso E (2005). Oxycodone. J Pain Symptom Manage 29: S47–S56.

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, et al. (2015). Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. Drug Des Devel Ther 9: 695–706.

Kokki H, Rasanen I, Reinikainen M, Suhonen P, Vanamo K, Ojanpera I (2004). Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 43: 613–622.

Kokki M, Valitalo P, Kuusisto M, Ranta VP, Raatikainen K, Hautajarvi H, et al. (2014). Central nervous system penetration of oxycodone after intravenous and epidural administration. Br J Anaesth 112: 133–140.

Kokubun H, Yoshimoto T, Hojo M, Fukumura K, Matoba M (2014). Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. J Pain Palliat Care Pharmacother 28: 338–350.

Kosmidis K, Argyrakis P (2003) Fractal kinetics in drug release from finite fractal matrices. J Chem Phys 119:6373–6377

Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461–479.

Li CG, Huang XE, Li Y, Lu YY (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev 12: 2477–2478.

Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL (2012). Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol 52: 600–606.

Lux EA, Janecki M, Maritz MA (2014). Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet. Curr Med Res Opin 30: 2365–2375.

Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR (1996). Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 42: 747–756.

Mehta V, Alaward S, Kuravinakop S, Nikolic S (2014). Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives. Pain Phys 17: 415–424.

Mundin GE, Smith KJ, Mysicka J, Heun G, Kramer M, Hahn U, et al. (2012). Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times. Expert Opin Drug Metab Toxicol 8: 1495–1503.

Naito T, Tashiro M, Ishida T, Ohnishi K, Kawakami J (2013). Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. J Clin Pharmacol 53: 812–818.

Pang KS, Rowland M. (1977) Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 5:625–653.

Poeelaert J, Koopmans-Klein G, Dho¨h A, Louis F, Gorissen M, Loge D, et al. (2015) .Treatment with prolonged-release
oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther 784–792.

Radbruch L, Nauck F (2002). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Schmerz 16: 186–193.

Ross FB, Smith MT (1997). The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73: 151–157.

Smith MT (2008). Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol. 21: 596–601.

Soderberg Lofdal KC, Andersson ML, Gustafsson LL (2013). Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs 73: 533–543.

Stessel B, Theunissen M, Fiddelers AA, Joosten EA, Kessels AG, Gramke HF, et al. (2014). Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. Curr Ther Res Clin Exp 76: 120–125.

Takala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT (1997). Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 41: 309–312.

Tan Q, Jiang R, Xu M, Liu G, Li S, Nanosized Zhang J (2013). Sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics. Int J Nanomed 8: 737–745.

Tegon G, Pulzato L, Passarella L, Guidolin D, Zusso M, Giusti P (2009). Randomized placebo-controlled trial on local applications of opioids after hemorrhoidectomy. Tech Coloproctol 13: 219–224.

Trescot AM, Datta S, Lee M, Hansen H (2008). Opioid pharmacology. Pain Phys 11: S133–S153.

Vallejo R, Barkin RL, Wang VC (2011). Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Phys 14: E343–E360.

Vk P (1987). The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharmacokinet Biopharm 15: 681–686.

Zhou H (2003). Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43: 211–227.